Healthcare ❯Pharmaceuticals ❯Obesity Treatments ❯Weight Loss Drugs
Intensified competition from Eli Lilly's Zepbound and compounded semaglutide products has led to flat prescriptions, underwhelming trial results, and a 25% share drop in March 2025.
